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Abstract
Certain species of pathogenic bacteria damage tissues by secreting cholesterol- 
dependent cytolysins, which form pores in the plasma membranes of animal cells. 
However, reducing cholesterol protects cells against these cytolysins. As the first 
committed step of cholesterol biosynthesis is catalyzed by squalene synthase, we ex-
plored whether inhibiting this enzyme protected cells against cholesterol- dependent 
cytolysins. We first synthesized 22 different nitrogen- containing bisphosphonate 
molecules that were designed to inhibit squalene synthase. Squalene synthase inhibi-
tion was quantified using a cell- free enzyme assay, and validated by computer mode-
ling of bisphosphonate molecules binding to squalene synthase. The bisphosphonates 
were then screened for their ability to protect HeLa cells against the damage caused 
by the cholesterol- dependent cytolysin, pyolysin. The most effective bisphosphonate 
reduced pyolysin- induced leakage of lactate dehydrogenase into cell supernatants by 
>80%, and reduced pyolysin- induced cytolysis from >75% to <25%. In addition, this 
bisphosphonate reduced pyolysin- induced leakage of potassium from cells, limited 
changes in the cytoskeleton, prevented mitogen- activated protein kinases cell stress 
responses, and reduced cellular cholesterol. The bisphosphonate also protected cells 
against another cholesterol- dependent cytolysin, streptolysin O, and protected lung 
epithelial cells and primary dermal fibroblasts against cytolysis. Our findings imply 
that treatment with bisphosphonates that inhibit squalene synthase might help protect 
tissues against pathogenic bacteria that secrete cholesterol- dependent cytolysins.
K E Y W O R D S
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1 |  INTRODUCTION
Pathogenic bacteria often secrete pore- forming toxins 
that cause leakage of cytosolic molecules, cytolysis, tissue 
damage, and disease in animals.1 The most common class 
of pore- forming toxins are the cholesterol- dependent cytol-
ysins. These cytolysins bind and form pores in cholesterol- 
rich areas of the plasma membrane of animal cells. The 
dependence of these cytolysins on cholesterol can be ex-
ploited because reducing cellular cholesterol can protect 
cells against damage.2– 5 This cytoprotection allows tissues 
to tolerate the presence of pathogenic bacteria that secrete 
cholesterol- dependent cytolysins.3,4 However, as cholesterol 
is fundamental for cell physiology, it is challenging to find 
compounds that alter cellular cholesterol sufficiently to pro-
tect cells against cholesterol- dependent cytolysins, without 
adverse side effects on cell viability.
Pathogenic bacteria secrete cholesterol- dependent cytoly-
sins as monomers, which assemble into multimers that insert 
into cholesterol- rich areas in plasma membranes to form β 
barrel pores.1,2,6 These stable pores are about 30 nm diame-
ter and lead to widespread changes in cells. There is initially 
membrane depolarization, leakage of potassium ions within 
5 minutes of challenging cells with a cholesterol- dependent 
cytolysin, and activation of MAPK cells stress responses. 
Changes in cell shape occur within 15 minutes, accompa-
nied by leakage of cytosolic proteins, such as lactate dehy-
drogenase (LDH), leading to reduced cell viability within 
2 hours.2,7– 10 Commonly studied cytolysins include pyoly-
sin produced by Trueperella pyogenes, which cause purulent 
diseases in farm animals, and streptolysin O produced by β- 
hemolytic group A Streptococci, which cause sore throats 
and impetigo in children.11,12 In particular, pyolysin causes 
damage to endometrial epithelial and stromal cells, leading to 
postpartum uterine disease, which affects about 40% of dairy 
cattle annually.2,13 Similarly, streptolysin O is thought to cause 
damage to the cells of the pharynx, contributing to the 37% 
of cases of pharyngitis associated with group A Streptococci 
in children over 5 years old.14 Other diseases associated with 
cholesterol- dependent cytolysins include pneumonia, septi-
cemia and meningitis caused by Streptococcus pneumoniae, 
which secretes pneumolysin; bacterial vaginosis caused by 
Gardnerella vaginalis, which produce vaginolysin; and gas 
gangrene caused by Clostridium perfringens, which secretes 
perfringolysin.1,5,15– 17 Pyolysin is particularly amenable to in 
vitro studies since it does not require thiol- activation, unlike 
most other cholesterol- dependent cytolysins.18 Pyolysin and 
streptolysin O depend on accessible cholesterol to form pores 
in the plasma membrane of cells,2,19 but pores only form 
when membranes contain >35 mol% cholesterol.6,19 Thus, 
reducing cellular cholesterol is an attractive strategy to pro-
tect cells against these cytolysins and help animals tolerate 
pathogen.13,20,21
The abundance of cellular cholesterol partially depends 
on cholesterol biosynthesis, starting with the mevalonate 
pathway converting acetyl- CoA to the isoprenoid farnesyl 
diphosphate.22 Statins inhibit the rate- limiting enzyme in 
the mevalonate pathway, HMG- CoA reductase, which re-
duces cholesterol biosynthesis, and can protect cells against 
cholesterol- dependent cytolysins.3,23 However, statins also 
deplete isoprenoids in cells, and have side effects in patients, 
such as muscle cramps, prompting a search for other inhib-
itors of cholesterol biosynthesis. Squalene synthase cata-
lyzes conversion of farnesyl diphosphate to squalene in the 
first committed step of cholesterol biosynthesis.24 Inhibitors 
of squalene synthase include the fungus- derived zaragozic 
acids, and alkoxy- aminobenzhydrol derivatives, but none 
are in clinical use due to unfavorable toxicity profiles.25– 27 
However, some nitrogen- containing bisphosphonates inhibit 
squalene synthase, and are likely to be safe because other 
bisphosphonates, which inhibit the enzyme that synthesizes 
farnesyl diphosphate, are safely used to treat osteoporosis.28,29
Here we tested the hypothesis that using bisphospho-
nates to inhibit squalene synthase would protect tissue cells 
against cholesterol- dependent cytolysins. The first step in our 
methodology was to design and synthesize bisphosphonates 
that inhibit squalene synthase. We then used epithelial cells, 
which are often the first point of contact with pathogens, 
to screen the bisphosphonates for cytoprotection against 
cholesterol- dependent cytolysins and to identify a lead mol-
ecule. Finally, we examined the ability of the lead molecule 
to protect other tissue cells against the damage caused by 
cholesterol- dependent cytolysins.
2 |  METHODS
2.1 | General procedures for synthesis of 
nitrogen- containing bisphosphonates
The chemicals used for synthesis were analytical quality 
or better, and purchased from Sigma- Aldrich (Gillingham, 
Dorset, UK), Apollo Scientific (Stockport, Cheshire, UK) and 
Thermo Fisher Scientific (Loughborough, UK). Reactions 
were carried out in an inert atmosphere of argon. All glass-
ware was cleaned with acetone and water and dried in the 
oven before use.
Tetralkyl esters of N- substituted aminobisphosphonates 
were designed based on previously synthesized compounds 
that inhibit squalene synthase,30,31 and prepared using two 
methods described previously.32,33
Method A.32 To a cold solution (ice/NaCl bath −10°C) of 
isonitrile and (0.050 mol, 1 eq), triethyl phosphite (0.1 mol, 
2 eq) in 100 mL dichloromethane (DCM), cold (−10°C) 
4 M HCl (0.15 mol in 1,4- dioxane) was added dropwise and 
the reaction mixture was stirred for approximately 1.5 hours 
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(Figure 1A). The resulting reaction mixture was further di-
luted by addition of another portion of 100 mL DCM and 
then reaction mixture was washed with a cold (0°C) solution 
of 5 × 100 mL saturated NaHCO3. The organic phase was 
collected and dried over anhydrous Na2SO4, solution filtered, 
and the solvent removed under reduced pressure to give 
F I G U R E  1  Synthesis of nitrogen- containing bisphosphonates. A, Synthesis of N- substituted aminomethylidenebisphosphonates from 
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yellow to dark brown oil as described further in Supporting 
Information Figure S1.
Method B,33 a mixture of amine (Figure 1B), triethyl or-
thoformate and diethyl phosphite was stirred at 110°C for 
24 hours. The reaction mixture was cooled, and the volatiles 
removed under reduced pressure.
Hydrolysis of the bisphosphonate tetraesters was carried 
out following the McKenna procedure.34 Neat bromotrimeth-
ylsilane (TMSBr, 15 eq) was added dropwise to the tetraester 
and the resulting mixture was stirred for 24 hours at room 
temperature; subsequently volatiles were removed in vacuo 
and resulting residue was dissolved in methanol and stirred 
at room temperature for 1 hour. Solvent was removed under 
reduced pressure and the resulting typically white solid was 
recrystallized.
Compounds were characterized by 1H, 13C, 31P and 19F 
NMR spectra analyzed with Avance 400 or Avance 300 NMR 
spectrometers (Bruker, Coventry, UK); and, mass spectra 
analyzed using an LCT Premier XE spectrometer (Waters, 
Elstree, Hertfordshire, UK) fitted with a 1525 Micro binary 
HPLC pump. Compound characterization is presented in 
Supporting Information Figure S1.
2.2 | Protein expression and purification
Plasmid pET21d- His harboring a gene for human 
squalene synthase containing a N- terminal hexa- histidine- 
tag (Epoch, Missouri City, Texas) was transformed in 
BL21- CodonPlus (DE3)- RP competent bacteria (Agilent 
Technologies, Santa Clara, CA) and incubated overnight 
at 37°C. One colony was inoculated in 10 mL Luria Broth 
with 100 mg/L ampicillin overnight at 37°C, and then in-
oculated into 3 L Terrific Broth with 100 mg/L ampicillin 
and incubated with shaking at 250 rpm at 37°C until 0.6 to 
0.8 OD600 was reached. The flask was cooled to 4°C for 1 
h, and expression of squalene synthase induced using IPTG 
(120 mg/L, isopropyl β- D- 1- thiogalactopyranoside) 
with shaking at 250 rpm for 2 d at 16°C. The bacte-
ria were pelleted by centrifugation at 22,790 × g for 30 
minutes at 4°C (Sorvall RC5B centrifuge), and stored 
at −20°C. Cell pellets were resuspended in 50 mM 
3- morpholinopropane- 1- sulfonic acid (MOPS buffer, pH 
7.2) with 0.5% sodium deoxycholate, disrupted by soni-
cation (40% amplitude for 3 minutes with 5 s on/10 s off 
cycles), and centrifuged at 22,790 ×g for 25 minutes. The 
supernatant was discarded, and protein recovered by adding 
MOPS buffer containing 1% Tween 80, and then 1 M NaOH 
until the solution became clear. The solution was stirred at 
4°C for 30 minutes before addition of 2- mercaptoethanol, 
and 1 M HCl to pH 7.2. The suspension was centrifuged at 
22,790 ×g for 30 minutes, and the supernatant loaded into 
a 0.5 mL Ni- NTA column equilibrated with buffer (50 mM 
MOPS, 30 mM NaCl, 20 mM imidazole, pH 7.2) and eluted 
using a 20 to 500 mM imidazole gradient. Following SDS- 
PAGE analysis, fractions containing squalene synthase (47 
kDa) were pooled and concentrated to a final volume of ~3 
mL using a Microcon 30 kDa centrifugal filter unit with 
Ultracel- 30 membrane (Merck, Watford, Hertfordshire, 
UK). The concentrate was then dialyzed with 50 mM phos-
phate buffer containing 1% Tween 80, 2% isopropanol, 10 
mM MgCl2 and 1 mM 1,4- dithiothreitol. The concentration 
of protein was measured using a Bradford Assay (Thermo 
Fisher Scientific, Waltham, MA), according to the manu-
facturer’s instructions.
2.3 | Squalene synthase activity assay
The assay used for enzyme activity was modified from previ-
ously described methods.35– 37 Each assay contained 50 mM 
phosphate (pH 7.4), 10 mM MgCl2, 1% (v/v) Tween- 80, 10% 
(v/v) 2- propanol, 1 mM DTT, 1 mg/ mL BSA, 1 mM NADPH, 
farnesyl diphosphate and 0.1 μM squalene synthase in a total 
volume of 200 μL in 1 mL eppendorfs. Reactions were pre- 
incubated at 37°C without the substrate for 10 minutes, and 
then another 10 minutes after addition of 3H- farnesyl diphos-
phate. [1- 3H]- farnesyl diphosphate (20 Ci/mMol, American 
Radiolabeled Chemicals, Saint Louis, USA) was diluted by 
adding cold farnesyl diphosphate to give final activity around 
24  000 dpm/μM. Reactions were quenched with 40% KOH 
solution in water/methanol 1/1 (v/v). Solid NaCl was added to 
saturate the mixture. The mixture was then extracted with 3 × 
1 mL of hexane containing 0.5% (v/v) squalene and extracts were 
passed through a short pipette column containing silica gel. The 
column was washed with 1 mL of toluene containing 0.5% (v/v) 
squalene. The radioactivity of the eluent was measured in 15 mL 
scintillation cocktail (Opti- Fluor purchased from Perkin Elmer) 
using a QuantaSmart scintillation counter (Perkin Elmer).
The inhibitory activity of synthesized nitrogen- containing 
bisphosphonates against squalene synthase was determined by 
incubation with [squalene synthase] = 0.5 µM, [NADPH] = 
1 mM, [1- 3H]- farnesyl diphosphate = 10 µM for 10 min-
utes at 37°C in the range of concentrations of 0.1 nM – 100 
µM. Steady- state kinetic parameters of squalene synthase 
were measured by incubation with [squalene synthase] = 
0.1 µM, [NADPH] = 1 mM, and range of concentrations of 
[1- 3H]- farnesyl diphosphate = 0- 40 µM for 10 minutes at 
37°C (Supporting Information Figure S2). The kcat and 
KM were found to be 0.0024 s
−1 and 3.36 µM respectively. 
Thompson et al. 1998 measured steady state kinetic param-
eters using the same methodological approach and received 
KM values between 1 and 2.8 µM which differ slightly to those 
reported here.35 Differences between steady state kinetic pa-
rameters based on the method used have been reported for 
other terpene synthases.
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2.4 | In silico docking studies
In silico docking studies were performed using a combina-
tion of empirical and force- field approaches incorporated 
within an in- house pipeline called “Shipyard”, which is used 
for high throughput virtual screening of protein- ligand dock-
ings. The structure of human squalene synthase was obtained 
from the RCSB Protein Data Bank (PBD, 3VJC) in complex 
with zaragozic acid. The squalene synthase protein structure 
and cofactors were prepared using the Chimera software to 
correct inconsistencies in the structure including the removal 
of solvent and crystallization additives.38 Protonation and 
partial charge calculations for each residue and cofactor were 
undertaken using the Antechamber software,39 a mapping of 
all pockets and grooves was generated using Sphgen,40 and 
the electrostatic field in the 3D volume of squalene synthase 
was pre- calculated with GRID.41 The binding pockets of 
squalene synthase were determined using DoGSiteScorer.42 
Output of the binding site search was verified manually via 
comparison with the original crystal structure. All ligand 
structures were subjected to the Open Babel system to make 
hydrogen atoms explicit,43 and the Balloon package was 
used to generate minimal- energy 3D structures,44 with partial 
charges assigned to each ligand.45
To generate the 10 best poses for ligands in the squalene 
synthase protein docking was performed using DOCK 646 
and AutoDock Vina,47 which assign a binding energy score 
and rank, alongside the DrugScoreX atom distance profile 
affinity calculations. Further physicochemical docking pa-
rameters were analyzed to investigate simulated squalene 
synthase- ligand interactions in more detail (Table 1, 
Supporting Information Table S1). Parameters most closely 
associated with the strong interactions observed with the pos-
itive controls were identified to provide further insight into 
potential mechanisms of interaction. Images of best poses of 
selected candidates were generated in Chimera.
2.5 | Cell culture
Experiments used newly purchased HeLa cervical epithelial 
cells (ATCC CCL- 2, ATCC, Manassas, VA, USA), A549 
lung epithelial cells (ATCC CCL- 185), and primary normal 
human dermal fibroblasts (C- 12302, Promocell, Heidelberg, 
Germany). Cells were cultured in 75 cm2 tissue culture flasks 
(Greiner Bio- One, Stonehouse, UK) with complete culture 
medium, incubated at 37°C in humidified air with 5% CO2, 
and passaged every 2 to 3 days. Complete culture medium 
for HeLa cells comprised DMEM (Thermo Fisher Scientific, 
Perth, UK) supplemented with 10% fetal bovine serum and 
1% antibiotic antimycotic solution (Sigma- Aldrich), and for 
A549 cells comprised RPMI1640 (Thermo Fisher Scientific) 
supplemented with 5% fetal bovine serum, 1% antibiotic 
antimycotic solution and 1% glutamine (Sigma- Aldrich). 
Complete culture medium for dermal fibroblasts com-
prised Fibroblast Growth Medium 2 with supplement mix 
(Promocell).
The HeLa and A549 cells were seeded at 50,000 cells/mL 
and dermal fibroblasts at 14,000 cells/mL, using 1 mL/well 
complete culture medium in 24- well culture plates (TPP, 
Trasadingen, Switzerland]. When cells were 90% conflu-
ent, medium were replaced with serum- free culture medium 
containing vehicle or treatments, and for the durations spec-
ified in Results. Treatments were the synthesized nitrogen- 
containing bisphosphonates, or zaragozic acid, atorvastatin, 
alendronate, methyl- β- cyclodextrin, farnesyl diphosphate or 
geranylgeranyl diphosphate (all Sigma- Aldrich). The cells 
were then challenged with serum- free control medium or 




Inhibition of squalene synthase 
by acid
Inhibition of squalene 
synthase by ester
MPEX009 C8H12NO7P2 297 No No
MPEX077 C4H10NO6P2 231 No No
MPEX083 C11H13NO6P2 340 No No
MPEX084 C5H15N2O6P2 262 No No
MPEX098 C5H15NO6P2 247 Yes No
MPEX099 C4H13NO7P2 249 Yes No
MPEX100 C7FH10NO6P2 285 No No
MPEX101 C4H12N06P2 233 No No
MPEX102 C5H14NO6P2 247 No No
MPEX103 C15H19NO6P2 371 No No
MPEX122 C7H16N2O7P2Na4 394 No No
MPEX211 C8H19NO7P2 303 Yes Not applicable
Note: n = 23. Inhibitory activity of synthesized bisphosphonic acids and corresponding esters against human squalene synthase in a cell- free system.
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medium containing pyolysin or streptolysin O, in the con-
centrations and durations specified in Results. Pyolysin was 
generated from the pGS59 plasmid (a generous gift from Prof 
BH Jost, University of Arizona, USA), as described previ-
ously.2 Streptolysin O was purchased and used following the 
manufacturer’s instructions (Sigma- Aldrich). At the end of 
the experiment, supernatants were collected and stored at 
4°C for measurement of LDH, and cell viability was mea-
sured as described below.
For measurement of cholesterol, potassium, or proteins 
by Western blot, HeLa or A549 cells were seeded at 50,000 
cells/mL in 3 mL complete culture medium in 6- well plates 
(TPP). When cells were 90% confluent, media were replaced 
with serum- free culture media containing vehicle, MPEX098, 
zaragozic acid or methyl- β- cyclodextrin for 24 hours, and 
the cells were then challenged with control serum- free me-
dium or medium containing pyolysin or streptolysin O, in 
the concentrations and durations specified in Results. Total 
cellular cholesterol was measured using the Amplex Red 
Cholesterol Assay Kit (Thermo Fisher Scientific), and abun-
dance normalized to protein abundance (DC assay, Sigma- 
Aldrich), according to the manufacturers’ instructions. For 
the measurement of potassium, the cells were washed three 
times with choline buffer (pH 7.4, 120 mM choline chloride, 
0.8 mM MgCl2, 1.5 mM CaCl2, 5 mM citric acid, 5.6 mM 
glucose, 10 mM NH4Cl, 5 mM H3PO3, all Sigma- Aldrich), 
and then challenged with choline buffer (control) or cho-
line buffer containing pyolysin. The supernatants were 
collected after 10 minutes and potassium measured using 
a Jenway PFP7 flame photometer, according to the manu-
facturer’s guidelines. For Western blotting, cells were col-
lected in PhosphoSafe Extraction Reagent (Merck, Watford, 
Hertfordshire, UK) and stored at −20°C.
2.6 | Cell viability and LDH assay
The viability of HeLa and A549 cells was evaluated using 
the MTT assay, as described previously.48 Briefly, cells were 
incubated for 2 hours with 1 mg/mL MTT (tetrazolium dye 
3- (4,5- dimethylthiazol- 2- yl)- 2,5- diphenyltetrazolium bro-
mide, Sigma- Aldrich] in serum- free medium. Supernatants 
were removed, cells lysed using 300 µL/well DMSO, and op-
tical density measured (OD570) using a POLARstar Omega 
plate reader (BMG Labtech, Ortenberg, Germany). The vi-
ability of dermal fibroblasts was evaluated by incubating 
cells for 6 hours with the Alamar Blue Cell Viability Reagent 
(Thermo Fisher Scientific), and the enzymatic reduction of 
resazurin to resorufin measured using a POLARstar Omega 
microplate reader (540/580 nm excitation/emission).
The activity of LDH in cell culture supernatants was mea-
sured as described for the Lactate Dehydrogenase Activity 
Assay Kit (Sigma- Aldrich). Briefly, as LDH catalyzes 
conversion of lactate to pyruvate, the reduction of NAD+ to 
NADH is quantified by conversion of iodonitrotetrazolium 
chloride to red formazan, using phenazine methosulphate as 
an electron carrier. Standards (0, 5, 10, 15, 20, 25 nmoles 
NADH) or samples were added in duplicate to a 96- well half- 
area plate (Greiner Bio- One, 20 µL/well), with 30 µL/well 
buffer (0.2 M Tris buffer, pH 8.2). To initiate the reaction, 
50 µL freshly prepared assay mix (54 mM lactate, 0.66 mM 
iodonitrotetrazolium chloride, 0.28 mM phenazine and 1.3 
mM NAD+ in 0.2 M Tris buffer, pH 8.2; all Sigma) was added 
to each well. The OD450 was measured using a POLARstar 
Omega plate reader, initially and following incubation at 
37°C for 30 minutes, and LDH activity calculated following 
the manufacturer’s instructions.
2.7 | Western blotting
Samples were diluted to 20 μg/mL in a 1:5 ratio with 
Laemelli sample buffer, heated for 10 minutes at 95°C, and 
subjected to SDS- PAGE on a 12% polyacrylamide gel, using 
All Blue Prestained Protein Standards (Bio- RAD, Watford, 
Hertfordshire, UK). Proteins were transferred to Hybond P 
0.45 μm PVDF membrane (Fisher Scientific), blocked for 
1 hour in blocking buffer (5% BSA, 20 mM Tris pH 7.6, 
137 mM NaCl and 0.1% v/v Tween 20; all Sigma- Aldrich), 
and then incubated overnight at 4°C in blocking buffer with 
1:1000 dilution of primary antibody for total and phosphoryl-
ated JNK, p38, and ERK (Supporting Information Table S2). 
The membrane was washed 5× in wash buffer (20 mM Tris 
pH7.6, 125 mM NaCl, 0.1% v/v Tween 20) and bound anti-
bodies identified by incubation for 1 hour at room tempera-
ture with 1:1000 HRP- linked anti- mouse IgG or anti- rabbit 
IgG (Cell Signaling Technology Inc, Danvers, MA, USA), 
washed 5× in wash buffer, and visualized by chemilumines-
cence (Clarify Western ECL Substrate, Bio- RAD) and a BIO- 
RAD ChemiDoc XRS system. The membrane was stripped 
using Restore Western Blot Stripping Buffer (Thermo Fisher 
Scientific) to detect another MAPK, or alpha- tubulin (New 
England Biolabs, Hitchin, Hertfordshire, UK). The density of 
protein bands was analyzed by ImageJ.
2.8 | Cell imaging
Cells were plated at a density of 50,000/mL for HeLa and 
14,000/mL for dermal fibroblasts on coverslips in 24- well 
plates, and incubated for 24 hours (HeLa) or 48 hours (der-
mal fibroblasts) in complete culture medium at 37°C in hu-
midified air with 5% CO2. Cells were washed three times 
with PBS, fixed with 4% paraformaldehyde, washed three 
times, and permeabilized with 0.2% Triton X- 100 in PBS. 
Cells were then washed three times in PBS and blocked with 
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0.1% Triton X- 100 with 1% BSA in PBS for 1 hour, and sub-
sequently probed with 1:1000 Alexa Fluor 555 Phalloidin 
(Thermo Fisher Scientific) in blocking buffer to visualize 
actin, or 50 µg/mL filipin III from Streptomyces filipinensis 
(Sigma- Aldrich) to visualize cholesterol within the cellular 
membranes.49 Cells were washed three times in PBS and 
coverslips mounted on slides using mounting medium with 
DAPI (Vector Laboratories Inc; Burlingame, CA). Cell mor-
phology and actin localization were analyzed with an Axio 
Imager M1 upright fluorescence microscope (Zeiss, Jena, 
Germany) and images captured using an AxioCamMR3. Cell 
cholesterol was analyzed using a LSM710 confocal micro-
scope (Zeiss) with the Zeiss Zen 2010 software. Images were 
captured using an 63x oil objective using the channel range 
410 to 476 nm. The coverslips were subjected to identical 
exposure times and conditions.
2.9 | Statistical analysis
Data are presented as mean (SEM). The statistical unit was 
the independent cell passages for each experiment. Statistical 
analyses were performed using Prism 7 (GraphPad Software, 
San Diego, CA), with significance ascribed when P < .05. 
Data were examined for normality and normally distributed 
data analyzed by student’s t test, or ANOVA with Dunnett’s 
or Sidak post- hoc tests, as reported in Results. Non- parametric 
data were explored using the Mann- Whitney test, multiple t 
test with Holm- Sidak post hoc test, or Kruskal- Wallis test 
with Dunn’s post hoc test, as specified in Results
3 |  RESULTS
3.1 | Synthesis of nitrogen- containing 
bisphosphonates
We designed nitrogen- containing bisphosphonates that we 
predicted might inhibit squalene synthase based on estab-
lished bisphosphonates that inhibit squalene synthase,30,31 
and that were tractable for laboratory synthesis.32,33 The bis-
phosphonates were synthesized using two different strategies. 
First, tetralkyl esters of N- substituted aminobisphosphonates 
were prepared using the method previously described by 
Goldeman et al (Figure 1A).32 Briefly, isonitriles were con-
verted to isonitrilium salts by the addition of 4 M HCl solu-
tion in 1,4- dioxane, reacted with triethylphosphite to create 
the intermediate phosphonium salt, which transforms into 
diethyl N- substituted iminomethylidenephosphonate, and 
then undergoes an Arbuzov- like reaction to yield triethyl N- 
substituted aminomethylidenebisphosphonate.32,50 Although 
the reaction is completed within 2 hours at temperatures as 
low as 0°C, few isonitriles are available commercially and so 
our second strategy was to use the method described previ-
ously by Suzuki et al (Figure 1B).33 Briefly, primary amines 
were treated for up to 24 hours with triethylorthoformate 
and diethyl phosphite at 110°C to yield tetraethyl bisphos-
phonates. Bisphosphonate tetraesters synthesized following 
both strategies were then hydrolyzed using bromotrimethyl-
silane (Figure 1C).51 Briefly esters were treated with excess 
bromotrimethylsilane for 24 hours at room temperature, and 
the resulting residue was treated with methanol for 1 hour to 
yield bisphosphonic acids.34 A reference squalene synthase 
inhibitor, 3- (1- piperidino)- 1- hydroxypropylidene- 1,1- bispho
sphonic acid (also known as PHPBP, Figure 1D; MPEX211), 
was synthesized as described previously.30,51
3.2 | Bisphosphonates inhibition of human 
recombinant squalene synthase
Squalene synthase activity was examined using a cell- 
free system and supplying tritiated farnesyl diphosphate 
(Supporting Information Figure S2). The ability to inhibit 
human squalene synthase was determined for the 11 syn-
thesized bisphosphonic acids, their 11 corresponding esters, 
and MPEX211 (Table 1). The IC50 of the effective inhibitors 
was measured, using MPEX211 as a reference compound 
with a previously reported IC50 of 0.31 µM.
30 In the present 
study, the IC50 for MPEX211 was 0.35 µM, for MPEX099 
was 2.42 µM, and for MPEX098 was 0.41 µM (Supporting 
Information Figure S3).
3.3 | In silico docking analysis
We used in silico ligand docking to further validate binding 
of the nitrogen- containing bisphosphonates to the active 
site of squalene synthase. Scores for compounds dock-
ing to squalene synthase (Table 2) were generated using a 
combination of empirical and force- field molecular dock-
ing approaches, applied to the protein structure and active 
site provided by the crystal structure of human squalene 
synthase in complex with zaragozic acid (3VJC, resolution 
1.89 Å, RCSB Protein Data Bank). Computer simulations 
indicated strong interactions between squalene synthase 
and established squalene synthase inhibitors, zaragozic 
acid (Figure 2A), lapaquistat (TAK- 475, Figure 2B) or 
RPR107393 (Figure 2C). Among the nitrogen- containing 
bisphosphonates synthesized in the present study, there 
were also strong interactions between squalene syn-
thase and MPEX098 or MPEX211 (Figure 2D,E), but not 
MPEX101 or MPEX102 (Figure 2F,G). We particularly 
focused on the DSX per contact score (Table 2), which is a 
knowledge- based scoring function that measures a basket 
of distance- dependent pair potentials, novel torsion angle 
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potentials and solvent accessible surface- dependent po-
tentials.52 The highest scores were derived for zaragozic 
acid, lapaquistat, and RPR107393, followed by MPEX098 
and MPEX211. Markedly lower scores were attained with 
MPEX101 and MPEX102.
3.4 | Screening for cytoprotection against 
cholesterol- dependent cytolysins
To screen the bisphosphonates for cytoprotection against 
cholesterol- dependent cytolysins, we first established in vitro 
cell models that were sensitive to cytolysins. Challenging 
HeLa or A549 epithelial cells with pyolysin or streptolysin O 
for 2 hours produced a concentration- dependent reduction in 
cell viability, as determined by MTT assay, and an increase 
in pore formation, as determined by the leakage of LDH into 
cell supernatants (Figure 3; ANOVA, P < .001). For subse-
quent cytoprotection studies we used 2.5 µg/mL pyolysin and 
9.4 µg/mL streptolysin O for HeLa cells, and 1.3 µg/mL py-
olysin and 9.4 µg/mL streptolysin O for A549 cells, because 
these concentrations reliably caused cytolysis. We used a 
2 hours challenge because the aim was to evaluate protection 
against cytolysins, rather than the ability of cells to recover 
after damage.
To screen for cytoprotection against cholesterol- dependent 
cytolysins, HeLa cells were treated for 24 hours with serum- 
free media containing 1 mM of each synthesized nitrogen- 
containing bisphosphonic acid or tetraester. The treatment 
media were removed, and the cells were then challenged for 2 
hours with control medium or medium containing 2.5 µg/mL 
pyolysin, and cell viability determined by MTT assay and 
pore formation estimated by measuring the leakage of LDH 
into cell supernatants (Figure 4). Five bisphosphonates were 
cytoprotective against pyolysin with cell viability > 50% 
compared with the vehicle treatment challenged with con-
trol (Figure 4A), and with LDH leakage < 50% of the vehi-
cle treatment challenged with pyolysin (Figure 4B; data not 
shown for three compounds that caused cytotoxicity per se).
Among the five cytoprotective candidate bisphospho-
nates, only MPEX098 inhibited squalene synthase in the 
cell- free assay (Supporting Information Figure S3), docked 








Zaragozic acid 0.893 35.261 −10.007 9.193 −124.243 −0.156
TAK- 475 2.355 30.972 −9.373 4.795 −112.592 −0.168
RPR107393 5.901 8.745 7.218 1.530 −102.991 −0.178
MPEX098 −45.359 72.648 −4.188 2.350 −51.049 −0.143
MPEX211 −27.600 66.359 −5.069 2.834 −70.083 −0.152
MPEX101 −53.635 76.086 −3.945 1.956 −42.173 −0.120
MPEX102 −50.485 77.032 −4.162 1.798 −33.102 −0.092
F I G U R E  2  In silico docking analysis. 
Images indicating docking outcomes using 
Chimera software with indicated point of 
contact marked by yellow lines. Docking 
shows established squalene synthase 
inhibitors, zaragozic Acid (A), TAK- 475 
(B) RPR107393 (C); synthesized nitrogen- 
containing bisphosphonates MPEX098 
(D), MPEX211 (E), MPEX101 (F), and 
MPEX102 (G)
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strongly with squalene synthase (Table 2), and 100 μM 
MPEX098 consistently protected HeLa cells against pyoly-
sin as effectively as 10 μM Zaragozic acid, which is a ref-
erence squalene synthase inhibitor (Figure 4C). Treatment 
with 100 µM MPEX098 caused 8 ± 3% HeLa cell toxicity 
per se, and zaragozic acid caused 13 ± 3% cytotoxicity, as 
determined by MTT assay (Figure 4C, control challenge; n = 
12). Cytoprotection against pyolysin was also evident within 
6 hours of treating HeLa cells with 100 μM MPEX098 and 
plateaued at 16 to 24 hours (Figure 4D). We selected a 24 
hour treatment with 100 μM MPEX098 as the candidate strat-
egy to explore cytoprotection against cholesterol- dependent 
cytolysins.
3.5 | MPEX098 cytoprotection against 
cholesterol- dependent cytolysins
To examine the wider potential for MPEX098 to protect cells 
against cholesterol- dependent cytolysins, HeLa and A549 
cells were treated for 24 hours with 100 μM MPEX098, and 
then challenged with a range of concentrations of pyolysin 
or streptolysin O. Treatment with MPEX098 protected HeLa 
cells against the detrimental effect of pyolysin on cell viabil-
ity, and reduced the leakage of LDH (Figure 5A,C, P < .001). 
The >80% cytoprotection of HeLa cells against pyolysin or 
streptolysin O following treatment with 100 µM MPEX098 
was similar to the > 90% cytoprotection of 10 µM zaragozic 
acid (Figure 5B,D: P < .001). This level of cytoprotection 
is also similar to the >70% cytoprotection against pyolysin 
or streptolysin O following treatment of HeLa cells with 
10 µM atorvastatin, which is a statin that inhibits HMG- CoA 
reductase, or the >80% cytoprotection with 10 µM alen-
dronate, which is a bisphosphonate that inhibits farnesyl 
diphosphate synthase (Supporting Information Figure S4). 
Both MPEX098 and zaragozic acid also protected A549 
cells against a range of concentrations of streptolysin O 
(Figure 5E– H). Collectively, these results provide evidence 
that treating cells with 100 μM MPEX098 provides cytopro-
tection against cholesterol- dependent cytolysins.
3.6 | Validating MPEX098 cytoprotection 
against cholesterol- dependent cytolysins
We next sought additional evidence for the cytoprotective ef-
fects of MPEX098 against cholesterol- dependent cytolysins. 
Treatment with MPEX098 reduced the toxin- induced leak-
age of potassium from HeLa and A549 cells challenged with 
pyolysin and streptolysin O, respectively (Figure 6A- D).
Furthermore, when challenged with pyolysin, HeLa cells 
shrank, lost angularity, and lost definition of the cytoskeleton 
(Figure 7A,B). However, treatment with MPEX098 prevented 
these changes in the cells (Figure 7C,D), in a similar man-
ner to the cholesterol- depleting agent methyl- β- cyclodextrin 
(Figure 7E,F), or zaragozic acid (Figure 7G,H).
Cells also mount stress responses when challenged with 
cholesterol- dependent cytolysins, typified by phosphorylation 
F I G U R E  3  Cellular sensitivity to 
cholesterol- dependent cytolysins. HeLa cells 
(A, B) or A549 cells (C, D) were challenged 
for 2 hours with control medium or medium 
containing the indicated concentrations of 
pyolysin or streptolysin O. Cell viability was 
determined by MTT assay [open circles], 
and pore formation estimated by measuring 
the leakage of LDH [filled squares] into 
cell supernatants. The data are from four 
independent cell passages, and are presented 
as mean (SEM)
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F I G U R E  4  Screening nitrogen- containing bisphosphonates for cytoprotection against pyolysin. HeLa cells were treated for 24 hours with 
serum- free medium containing vehicle or 1 mM of the indicated bisphosphonic acid or ester, prior to 2 hours challenge with control medium or  
2.5 µg/mL pyolysin. Cytoprotection against pyolysin was evaluated by MTT assay for cell viability and LDH assay for pore formation. The data are 
from three or four independent passages, and are presented as mean (SEM) percentage of vehicle challenged with control for cell viability (A), and 
vehicle challenged with pyolysin for LDH leakage (B; data not shown for cytotoxic bisphosphonates; ND, not detectable); the horizontal line marks 
the 50% level. Data were analyzed by ANOVA and compounds that show significant (P < .05) cytoprotection are in bold type and indicated by 
arrows. C, HeLa cells were treated for 24 hours with medium containing vehicle ( ),100 μM MPEX098 ( ) or 10 µM zaragozic acid ( ), and then 
challenged for 2 hours with control medium or 2.5 µg/mL pyolysin. Cell viability was evaluated by MTT assay. The data are presented as dot plots, 
with each dot an independent cell passage (n = 12); the line represents the mean and the values are the percentage of control. D, HeLa cells were 
treated for the indicated times with medium containing vehicle ( ) or 100 μM MPEX098 ( ), or 10 µM zaragozic acid ( ), and then challenged for 
2 hours with control medium or 2.5 µg/mL pyolysin. Cell viability was evaluated by MTT assay. The data are from 4 independent experiments and 
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of mitogen- activated protein kinases (MAPK).10,52 However, 
treating HeLa cells with MPEX098 limited pyolysin- induced 
phosphorylation of MAPKs, ERK, JNK and p38, in a similar 
manner to zaragozic acid (Figure 8, Supporting Information 
Figures S5 and S6).
Whilst MPEX098 protected HeLa and A549 cells 
against cholesterol- dependent cytolysins, one concern was 
that these are immortal cell lines. Therefore, we examined 
if MPEX098 protected normal human dermal fibroblasts 
against pyolysin. Treatment with ≥250 μM MPEX098 
protected the fibroblasts against cytolysis and reduced the 
leakage of LDH (Figure 9A,B). Treatment with MPEX098 
also helped the fibroblasts maintain the shape of their actin 
cytoskeleton when challenged with pyolysin (Figure 9C).
3.7 | MPEX098 alters cholesterol 
biosynthesis
As inhibiting squalene synthase may limit cholesterol biosyn-
thesis, cellular cholesterol was measured in HeLa and A549 
cells incubated for 24 hours in serum- free media containing a 
range of concentrations of MPEX098. Cholesterol abundance 
was reduced by 100 µM MPEX098 in HeLa cells, and by 
F I G U R E  5  Squalene synthase 
inhibitors protect cells against cholesterol- 
dependent cytolysins. HeLa cells (A- D) or 
A549 cells (E- H) were treated for 24 hours 
with serum- free medium containing vehicle, 
10 µM zaragozic acid (ZA), or 100 µM 
MPEX098. Cells were then challenged for  
2 hours with control medium or the 
indicated concentrations of pyolysin or 
streptolysin O, and cell viability evaluated 
by MTT assay (A, B, E, F) and pore 
formation by measuring the leakage of LDH 
into cell supernatants (C, D, G, H). The data 
are from four independent passages, and are 
presented as mean (SEM). The data were 
analyzed by ANOVA with Dunnett post 
hoc test; within challenge values differ from 
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200 µM MPEX098 in A549 cells (Figure 10A,B). Using con-
centrations that protect cells against pyolysin, the reduction in 
HeLa cellular cholesterol was 36% for methyl- β- cyclodextrin, 
25% for zaragozic acid and 15% for MPEX098 (Figure 10C). 
Further evidence for cholesterol depletion was provided by 
imaging cholesterol using filipin in HeLa cells (Figure 10D).
Reducing cholesterol biosynthesis by inhibiting squalene 
synthase also increases the accumulation of farnesyl diphos-
phate and geranylgeranyl diphosphate.53 To test whether 
increased abundance of isoprenoids might also affect cytopro-
tection against cholesterol- dependent cytolysins, HeLa cells 
were treated with farnesyl diphosphate or geranylgeranyl di-
phosphate prior to challenge with pyolysin. Treatment with ger-
anylgeranyl diphosphate but not farnesyl diphosphate (P = .12) 
increased cytoprotection against pyolysin (Figure 11).
4 |  DISCUSSION
In the present study, we synthesized nitrogen- containing bis-
phosphonates that were designed to inhibit squalene synthase, 
and screened these compounds for cytoprotection against 
cholesterol- dependent cytolysins. Bisphosphonates contain 
a functional group with a similar structure to diphosphate 
and can inhibit farnesyl diphosphate synthase or squalene 
synthase.28 Bisphosphonic inhibitors of farnesyl diphos-
phate synthase are widely used for the long- term treatment 
of osteoporosis, and have a high safety margin.29 Although 
nitrogen- containing bisphosphonate inhibitors of squalene 
synthase are not effective against osteoporosis, we found that 
nitrogen- containing bisphosphonates protected cells against 
damage caused by cholesterol- dependent cytolysins, in a sim-
ilar manner to the reference, zaragozic acid.54,55
We synthesized a library of 22 nitrogen- containing bis-
phosphonates using two approaches alongside the established 
bisphosphonate inhibitor of squalene synthase MPEX211 
(PHPBP).30,51 First, we used the method described by 
Goldeman et al,32 whereby a series of isonitriles were treated 
with triethyl phosphite, undergoing an Arbuzov- like reaction 
to generate nitrogen- containing bisphosphonate esters that 
were subsequently hydrolyzed. As the synthesis of isonitriles 
is difficult on the milligram scale, and where isonitrile sub-
strates were not commercially available, we used a second 
method, as described previously by Suzuki et al,33 employing 
F I G U R E  6  Treatment with squalene 
synthase inhibitors reduces potassium 
leakage. HeLa (A, B) or A549 (C, D) cells 
were treated for 24 hours in serum- free 
medium with vehicle, 10 µM zaragozic acid 
(ZA) or 100 µM MPEX098. Cells were 
then challenged with control choline buffer, 
or choline buffer containing 2.5 µg/mL 
pyolysin (A, C) or 9.4 µg/mL streptolysin 
O (B, D) for 10 minutes. Supernatants were 
collected and potassium concentrations 
measured using a flame photometer. The 
data are presented as mean (SEM) from 3 
or 4 independent cell passages. The data 
were analyzed by ANOVA with Dunnett 
post hoc test; within SLO or PLO challenge 
values differ between treatments (ZA or 
MPEX098) and vehicle, * P < .05,  
** P < .01
(A) (B)
(C) (D)
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simple amines heated with triethylorthoformate and diethyl 
phosphite. We used both a cell- free squalene synthase assay 
and in silico docking to evaluate the ability of the synthesized 
bisphosphonates to inhibit squalene synthase. Three bisphos-
phonates had in silico affinity for the active site of squalene 
synthase that was similar to zaragozic acid. The cell- free 
assay was consistent with the DSX per contact score, which 
is a scoring function for ligand- protein interactions.56
Six nitrogen- containing bisphosphonates protected HeLa 
cells against pyolysin, and we selected MPEX098 as a lead 
compound because it inhibited squalene synthase in a cell- 
free assay, docked strongly with squalene synthase, and con-
sistently protected HeLa cells against challenge with pyolysin 
at a concentration of 100 µM. Several lines of evidence sup-
ported the cytoprotective effect of MPEX098 against pyoly-
sin. First, treating cells with MPEX098 reduced the formation 
of pores when cells were challenged with pyolysin, as deter-
mined by reduced leakage of potassium ions and lactate de-
hydrogenase. Second, treating cells with MPEX098 reduced 
the expected MAPK stress response to pores formed by 
cholesterol- dependent cytolysins.8,10,52,57 Third, MPEX098 
treatment prevented the expected pyolysin- induced changes 
in cell viability and the actin cytoskeleton, which are likely 
caused by the pores in plasma membranes leading to alter-
ations in osmotic tension.58 Finally, MPEX098 also protected 
A549 human lung epithelial cells and primary human dermal 
fibroblasts against pyolysin, and protected HeLa cells against 
Streptolysin O. Although the concentration of MPEX098 
needed for cytoprotection was ten- fold higher than zaragozic 
acid, the IC50 of MPEX098 was 0.41 µM in a squalene synthase 
cell free assay, whereas the IC50 of zaragozic acid was 0.012 
µM.59 The IC50 of MPEX098 is similar to other bisphosphonic 
inhibitors of squalene synthase.28,60 The higher concentrations 
of MPEX098 and zaragozic acid needed to protect cells than 
implied by the IC50 values may reflect lower bioavailability 
or reduced lipophilicity, which prevents transcellular transport 
across the epithelial barriers.61 Zaragozic acid also caused cy-
totoxicity per se at 10 µM, compared with the 100 µM to 1 
mM cytotoxic concentration for the bisphosphonates.
Most cholesterol is located in the plasma membrane, 
where there are three functional pools of cholesterol: an 
essential pool, a sphingomyelin- bound pool, and a pool of 
F I G U R E  7  MPEX098 protects 
the actin cytoskeleton of HeLa cells 
challenged with pyolysin. HeLa cells 
were treated for 24 hours with serum- free 
medium containing vehicle (A, B), 100 
µM MPEX098 (C, D), 1 mM methyl- β- 
cyclodextrin (E, F), or 10 µM zaragozic acid 
(G, H). The cells were then challenged for 2 
hours with control medium (A, C, D, E) or 
2.5 µg/mL pyolysin (B, D, F, H). Cells were 
fixed and stained using phalloidin- Alexa555 
for actin (white) and DAPI for DNA (red). 
The images are representative of four 
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“labile” accessible cholesterol.62 Accessible cholesterol is 
bound by cholesterol- dependent cytolysins, usually when 
there is >35 mol% cholesterol in membranes.62,63 Thus, an 
obvious mechanism for protecting cells against cholesterol- 
dependent cytolysins is reducing the abundance of acces-
sible cholesterol, using compounds such as cyclodextrins 
or zaragozic acid.2,53,64– 66 For example, treatment with cy-
clodextrins or zaragozic acid protects fibroblasts against 
pyolysin.54 Compared with cyclodextrins or zaragozic acid, 
MPEX098 only reduced cholesterol in HeLa and A549 cells 
by 15% at most. This modest reduction may be sufficient to 
alter the accessible pool of cholesterol in the plasma mem-
brane.62,67 A potential alternative mechanism is via changes 
in isoprenoids because inhibiting squalene synthase increases 
the concentration of cellular farnesyl diphosphate and ger-
anylgeranyl diphosphate.53,68,69 Unfortunately, it is techni-
cally challenging to robustly measure cellular isoprenoids.70 
Therefore, in the present study, we examined the effect of 
treatment with isoprenoids, and we found that geranylgeranyl 
diphosphate protected cells against pyolysin. One possibil-
ity is that geranylgeranyl diphosphate may help sustain the 
actin cytoskeleton as alcohol derivatives of geranylgeranyl 
diphosphate affect the actin cytoskeleton via prenylation of 
Rho.68 Another possibility is changes in cellular cholesterol 
because geranylgeranyl diphosphate is a reverse agonist for 
Liver X receptors, which regulate the expression of squalene 
synthase and cholesterol efflux.71– 73 However, there are 
other potential mechanisms, including changes in oxysterols 
as increasing 25- hydroxycholesterol protects cells against 
cholesterol- dependent cytolysins, without altering choles-
terol abundance.74
Cytoprotection using MPEX098 may be able to protect 
tissues against pathogenic bacteria that secrete cholesterol- 
dependent cytolysins. Defense against pathogenic bacteria 
F I G U R E  8  Squalene synthase inhibitors alter MAPK phosphorylation. HeLa cells were treated for 24 hours with serum- free medium 
containing vehicle (V), 10 µM zaragozic acid (ZA) or 100 µM MPEX098 (098), prior to a 10 minutes challenge with control medium or 
medium containing 2.5 μg/well pyolysin (PLO). Cells were then collected for Western blotting for phosphorylated and total ERK and tubulin 
(A), phosphorylated and total JNK and tubulin (B), or phosphorylated and total p38 and tubulin (C). Representative images of four independent 
experiments are presented (left panel), and densitometry was performed on the blots [right panel] with data presented as mean (SEM) of the ratio of 
phosphorylated to total protein, normalized to tubulin, Within PLO challenge values differ between treatments (ZA or MPEX098) and vehicle  
** P < .01, *** P < .001
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depends on resisting and tolerating infections.75,76 Resistance 
is the function of immunity or antimicrobials, which aim to 
kill bacteria to limit the pathogen burden.63,75 Tolerance is 
the ability to limit the tissue damage caused by the patho-
gens.77 Tolerance mechanisms include neutralizing bacterial 
toxins and protecting cells against damage. Increasing toler-
ance to pathogenic bacteria is an attractive strategy because 
this reduces the risk of antimicrobial resistance. In partic-
ular, it may be possible to apply treatments parenterally, or 
directly to mucosae or skin, to prevent tissue damage caused 
by pathogenic bacteria that secrete cholesterol- dependent cy-
tolysins. For example, an intra- uterine infusion of a drug to 
reduce endometrial cellular cholesterol might protect against 
pyolysin- induced damage and help prevent postpartum uter-
ine disease in cattle caused by T. pyogenes, instead of using 
antibiotic treatments.2,13 Similarly, applying treatments via a 
spray or lozenge to the oropharynx that reduced pharyngeal 
epithelial cell cholesterol might protect against the 37% of 
F I G U R E  9  MPEX098 protects 
primary cells against pyolysin. Dermal 
fibroblasts were treated for 48 hours with 
serum- free medium containing vehicle or 
the indicated concentrations of MPEX098. 
Cells were then challenged for 2 hours with 
control medium or medium containing 
1 µg/mL pyolysin. Cell viability was 
measured using Alamar Blue (A), and pore 
formation estimated by LDH leakage into 
cell supernatants (B). The data are from four 
independent cell passages, and presented 
as mean (SEM). The data were analyzed 
by ANOVA with Dunnett’s multiple 
comparison post hoc test; within challenge, 
values differ from vehicle, *P < .05, **P < 
.01, ***P < .001. C, Cells were fixed and 
stained for actin using phalloidin- Alexa555 
(White) and DNA (Red). Images are 
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cases of pharyngitis associated with group A Streptococci in 
children.14
The present work extends previous findings that statins 
protect cells against vaginolysin and pneumolysin.3,23,78,79 
While both reduce cholesterol synthesis, statins and nitrogen- 
containing bisphosphonates differ in their action, depleting or 
increasing isoprenoids, respectively. Furthermore inhibiting 
squalene synthase may prevent squalene being a feedforward 
stimulus for cholesterol biosynthesis.80 The action of statins 
is also complicated by their lipophilic properties, whereby 
lipophilic simvastatin is more cytoprotective than hydrophilic 
pravastatin, independent of changes in cellular cholesterol, 
and may instead be associated with altering lipid raft compo-
sition and organization.79 In future work, it would be interest-
ing to explore whether nitrogen- containing bisphosphonates 
targeting squalene synthase also affect membrane lipid rafts.
In conclusion, the present study explored the cytoprotec-
tive effect of nitrogen- containing bisphosphonates, which 
were designed to inhibit squalene synthase to protect cells 
against cholesterol- dependent cytolysins. Although the 
mechanism of action remains elusive, we provide several 
lines of evidence that our lead bisphosphonate, MPEX098, 
provided cytoprotection against cholesterol- dependent cy-
tolysins. These findings imply that nitrogen- containing 
F I G U R E  1 0  MPEX098 reduces cellular cholesterol. HeLa (A, C) or A549 (B) cells were treated for 24 hours with vehicle or the indicated 
concentrations of MPEX098, 1 mM methyl- β- cyclodextrin (MβCD), or 10 µM zaragozic acid (ZA) in serum- free medium, and cholesterol and 
protein quantified. The data are presented as mean (SEM) from ≥ 4 independent cell passages, and were analyzed by ANOVA with Dunnett’s post 
hoc test; values differ from vehicle, *P < .05, ** P < .01, *** P < .001. D, HeLa cells were stained with filipin for cholesterol and images acquired 
using 40× objective and 340 nm excitation and 480 nm emission filters. Representative images of four independent experiments are shown. Scale 
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bisphosphonates might help protect tissues against 
pathogenic bacteria that secrete cholesterol- dependent 
cytolysins.
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